Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $10.2 million.

  • vTv Therapeutics' Total Current Liabilities rose 5820.36% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 5820.36%. This contributed to the annual value of $5.2 million for FY2024, which is 5106.88% down from last year.
  • As of Q3 2025, vTv Therapeutics' Total Current Liabilities stood at $10.2 million, which was up 5820.36% from $5.3 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Total Current Liabilities high stood at $12.7 million for Q1 2022, and its period low was $4.3 million during Q1 2025.
  • For the 5-year period, vTv Therapeutics' Total Current Liabilities averaged around $7.8 million, with its median value being $7.7 million (2022).
  • In the last 5 years, vTv Therapeutics' Total Current Liabilities tumbled by 5687.55% in 2021 and then skyrocketed by 14602.87% in 2022.
  • Over the past 5 years, vTv Therapeutics' Total Current Liabilities (Quarter) stood at $8.5 million in 2021, then decreased by 9.3% to $7.7 million in 2022, then soared by 37.77% to $10.6 million in 2023, then tumbled by 51.07% to $5.2 million in 2024, then skyrocketed by 95.59% to $10.2 million in 2025.
  • Its Total Current Liabilities stands at $10.2 million for Q3 2025, versus $5.3 million for Q2 2025 and $4.3 million for Q1 2025.